Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, 40-weeks Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects

NCT01002274 is registered in ClinicalTrials.gov with Health Ever Bio-Tech Co., Ltd. as lead sponsor.

NCT NCT01002274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01002274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, 40-weeks Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2010
Completion date
June 30, 2014
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, lower urinary tract symptoms